Effect of hypothyroidism on contractile performance of isolated end-stage failing human myocardium

Nancy S. Saad1,2,3*, Mohammed A. Mashali1,2,4*, Mohammad T. Elnakish1,2,3, Austin Hare1,2, Courtney M. Campbell1,2,5, Salome A. Kiduko1,2, Kyra K. Peczkowski1,2, Amanda W. Huang1,2, Farbod Fazlollahi1,2, Gina S. Torres Matias1,2, Amany A. E. Ahmed3, Bryan A. Whitson6, Nahush A. Mokadam6, Paul M. L. Janssen1,2,5*

1 Department of Physiology and Cell Biology, College of Medicine, The Ohio State University, Columbus, OH, United States of America, 2 Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH, United States of America, 3 Faculty of Pharmacy, Department of Pharmacology and Toxicology, Helwan University, Cairo, Egypt, 4 Faculty of Veterinary Medicine, Department of Surgery, Damanhour University, Damanhour, Egypt, 5 Division of Cardiovascular Medicine, Department of Internal Medicine, The Ohio State University, Columbus, OH, United States of America, 6 Division of Cardiac Surgery, College of Medicine, The Ohio State University, Columbus, OH, United States of America

☯ These authors contributed equally to this work.

* janssen.10@osu.edu

Abstract

The relationship between hypothyroidism and the occurrence and progression of heart failure (HF) has had increased interest over the past years. The low T3 syndrome, a reduced T3 in the presence of normal thyroid stimulating hormone (TSH), and free T4 concentration, is a strong predictor of all-cause mortality in HF patients. Still, the impact of hypothyroidism on the contractile properties of failing human myocardium is unknown. Our study aimed to investigate that impact using ex-vivo assessment of force and kinetics of contraction/relaxation in left ventricular intact human myocardial muscle preparations. Trabeculae were dissected from non-failing (NF; n = 9), failing with no hypothyroidism (FNH; n = 9), and failing with hypothyroidism (FH; n = 9) hearts. Isolated muscle preparations were transferred into a custom-made setup where baseline conditions as well as the three main physiological modulators that regulate the contractile strength, length-dependent and frequency-dependent activation, as well as β-adrenergic stimulation, were assessed under near-physiological conditions. Hypothyroidism did not show any additional significant impact on the contractile properties different from the recognized alterations usually detected in such parameters in any end-stage failing heart without thyroid dysfunction. Clinical information for FH patients in our study revealed they were all receiving levothyroxine. Absence of any difference between failing hearts with or without hypothyroidism, may possibly be due to the profound effects of the advanced stage of heart failure that concealed any changes between the groups. Still, we cannot exclude the possibility of differences that may have been present at earlier stages. The effects of THs supplementation such as levothyroxine on contractile force and kinetic parameters of failing human myocardium require further investigation to explore its full potential in improving cardiovascular performance and cardiovascular outcomes of HF associated with hypothyroidism.
Introduction

According to the American College of Cardiology, heart failure (HF) is a complex clinical syndrome that impairs the ability of the ventricle to fill with or eject blood [1]. HF represents a common final condition of several cardiac diseases [2]. The prevalence of HF continues to rise over time with the aging population. An estimated 6.2 million American adults ≥ 20 years of age (2.2%) had HF between 2013 and 2016 compared with an estimated 5.7 million between 2009 and 2012 [3]. Despite progress in treating HF over the past 15 years, the estimated increases in the morbidity and mortality rates is likely partially due to our lack of adequate understanding of the pathophysiological mechanisms of this syndrome [4].

Thyroid hormones (THs) play essential roles in cardiovascular homeostasis [5]. THs affect every structure of the heart and its specialized conducting system. T3 is the biological active thyroid hormone; in peripheral tissues T3 is mostly generated by 5'-monodeiodination of thyroxine (T4) [6]. Multiple experimental and clinical studies have focused on the relationship between thyroid hormone and the cardiovascular system [7–12]. The physiological effects of thyroid hormone are mostly mediated by its genomic nuclear effects through binding to thyroid hormone nuclear receptors (TRs). The occupancy of these receptors by T3 modify the rate of transcription of specific target genes [7,8] and in the absence of T3 they repress transcription [13]. Some of the important cardiac structural and functional proteins that are transcriptionally regulated by T3 are alpha myosin heavy chain (αMHC), voltage-gated K+ channels, β1 adrenergic receptors, malic enzyme and atrial and brain natriuretic hormone [7,8] while βMHC, phospholamban, the Na+/Ca2+ exchanger, and adenylyl cyclase type V and VI are negatively regulated genes that are repressed in the presence of T3 [7,8]. Thyroid hormone also upregulates sarcoplasmic reticulum calcium-activated ATPase 2 (SERCA2) and Na+/K+ ATPase and downregulates phospholamban [14]. These changes enhance contractile function and diastolic relaxation in the heart [14]. Moreover, T3 influences the sensitivity of the sympathetic system by increasing the number of myocardial adrenergic membrane receptors. T3 also leads to hemodynamic alterations in the periphery by decreasing systemic vascular resistance through relaxation of vascular smooth muscle. Renal perfusion as a consequence decreases and leads to activation of renin-angiotensin aldosterone system that leads to increased cardiac filling and modification of cardiac contractility [15,16]. Thyroid hormone enhances the release of vasodilatory mediators as a result of increasing metabolic and oxygen consumption [15]. Increasing resting heart rate and left ventricular contractility mediated by T3 are partially depending on its non-genomic mechanisms [17]. These effects of TH start very quickly and do not require the binding to nuclear receptors [18], otherwise they involve the transport of ions (calcium, sodium and potassium) across the plasma membrane, mitochondrial function, glucose and amino acid transport, and a variety of intracellular signaling pathways [8,18].

Disease of the thyroid gland often produces cardiac problems; it can worsen cardiac disease symptoms or can accelerate the underlying cardiac problem in a heart disease person as well as producing cardiac disease in people with healthy hearts. Untreated subclinical hyperthyroidism and hypothyroidism were found to be associated with the development of HF in diseased or healthy heart patients [19,20]. In the US general population, hypothyroidism is more prevalent than hyperthyroidism: 4.6% (0.3% clinical and 4.3% subclinical) compared to 1.3% (0.5% clinical and 0.7% subclinical), respectively, suggesting that low thyroid hormone conditions could be worth more concern. Nearly 13 million Americans are estimated to have undiagnosed hypothyroidism [21].

Decreased THs are considered to play a role in the progression of the HF since cardiac contractility, energy metabolism, and myocyte shape, as well as angiogenesis and fibrosis are all regulated by T3 [22–24]. Patients with hypothyroidism usually exhibit impaired ventricular relaxation related to reductions in the activity of the Ca2+-ATPase within the sarcoplasmic...
reticulum, increased expression of phospholamban, and associated reductions in intracellular calcium reuptake during diastole [8,25,26]. Moreover, both systolic and diastolic functions are impaired during effort, leading to decreased exercise tolerance for the slowed myocardial relaxation and the impaired left ventricular filling and vasodilatation during effort [9,27]. These hemodynamic abnormalities likely contribute to the heightened risk of incident HF associated with subclinical hypothyroidism as shown in an individual patient meta-analysis of the Thyroid Studies Collaboration [28]. Alterations in gene expression developed in the failing heart were found to be similar to the alterations induced in experimental hypothyroidism, suggesting that TH dysfunction has an important role in the progression of HF [29]. The low T3 syndrome, a reduced T3 in the presence of normal thyroid stimulating hormone (TSH), and free T4 concentration, is a strong predictor of all-cause mortality in HF patients [30].

In this study, we aimed to investigate the impact of hypothyroidism on force and kinetics of contraction/relaxation of failing myocardium obtained from patients with combined HF and hypothyroidism. This study could potentially help understand the influence of hypothyroidism on such hearts from the contractile point of view, which may help future studies find an appropriate targeted treatment that can improve cardiovascular performance and cardiovascular outcomes of such cases.

**Materials and methods**

**Human tissue procurement**

All human tissues studies were conducted with approval from the Institutional Review Board (IRB) of The Ohio State University and conform to the Declaration of Helsinki. In collaboration with Lifeline of Ohio Organ Procurement Program, non-transplantable donor hearts were acquired in the operating room. All end-stage failing hearts were acquired from patients undergoing cardiac transplantation at The Ohio State University Wexner Medical Center. Informed consents were obtained from cardiac transplant patients. Immediately after removal from the patients/donors, hearts were flushed with cardioplegic solution as described previously [31,32]. Over the past 11 years, a total of 214 hearts were procured. Of these, 55% (n = 119) were from patients who had end-stage HF, while the remaining (n = 95) were from donors with no apparent history of HF. Retrospective analysis of our data showed that 20% of HF patients (n = 24) had a history of hypothyroidism. Of these, contractility experiments were successfully performed, and data were collected from 9 procured hearts. Hence, contractile force and kinetics were comparatively assessed in myocardium dissected from: HF patients with a history of hypothyroidism (FH; n = 9), HF patients with no history of hypothyroidism (FNH; n = 9), and non-failing donors (NF; n = 9). Donor/patient demographics and hearts’ dimensions and ventricular wall thickness are provided in Tables 1 and 2.

In a recent study from our group, studying the impact of etiology on force and kinetics of left ventricular end-stage failing human myocardium, failing myocardium showed a relatively slower kinetics when stimulation frequency increased, muscle length stretched, and isoproterenol concentration increased (compared to non-failing) with a markedly slowing down of relaxation kinetics in myocardium from failing hearts of NICM origin [33]. The etiology disproportion between the two failing groups in our study, didn’t impact the contractile force outcomes as well as the kinetics parameters.

**Trabecula isolation**

For each heart, the left ventricle (LV) was rapidly transferred from the cardioplegic solution to a cold modified Krebs-Henseleit solution (K-H) containing 2,3-butanediol monoxime (BDM) [34], where uniform linear trabeculae were dissected by the aid of a stereo dissection
microscope. Muscles were transferred into custom-made setups as previously described [35], and the perfusion solution was exchanged for a BDM-free K-H solution, circulating at 37˚C. Stimulation was started at a baseline frequency of 0.5 Hz, and the CaCl$_2$ concentration of the solution was gradually raised to 2 mM over ~15 minutes. Muscles were gradually stretched (over a few minutes) to an optimal length ($L_{100}$ or $L_{opt}$), where a small increase in length resulted in nearly equal increase in active developed tension and resting tension. This length

Table 1. Donor demographic and characteristics of procured human hearts (NF; n = 9).

| ID # | Sex | Age | Race | BMI  | HW (g) | Overall dimensions (cm) | LV Wall (cm) | RV Wall (cm) | Septum (cm) |
|------|-----|-----|------|------|--------|-------------------------|-------------|-------------|-------------|
| NF1  | M   | 58  | C    | 32.1 | 512    | 13.5 10 9.5             | 1.7         | 0.9         | 1.9         |
| NF2  | F   | 62  | C    | 35.5 | 478    | 14.5 10.5 9.5           | 1.6         | 0.7         | 1.7         |
| NF3  | M   | 23  | C    | 33.9 | 462    | 9.5   14 9.5            | 1.8         | 0.7         | 1.6         |
| NF4  | F   | 38  | C    | 31   | 406    | 9.5   10 9.5            | 2.3         | 0.6         | 1.8         |
| NF5  | M   | 20  | C    | 25.9 | 324    | 9     13.3 8.5          | 1.8         | 1           | 1.4         |
| NF6  | F   | 55  | AA   | 24.5 | 350    | 8.5   11.5 8.5          | 1.5         | 0.4         | 1.8         |
| NF7  | F   | 51  | C    | 20.6 | 507    | 13.5 10 11.5           | 2           | 0.9         | 1.4         |
| NF8  | M   | 67  | C    | 29.2 | 527    | 15.3 11.8 11           | 2.2         | 0.8         | 2.9         |
| NF9  | F   | 43  | AA   | 20.9 | 605    | 10.5 13.5 10           | 2           | 0.8         | 2           |

AA, African American; BMI, body mass index; C, Caucasian; F, female; g, gram; HW, heart weight; LV, left ventricle; M, male; NF, non-failing; RV, right ventricle.

https://doi.org/10.1371/journal.pone.0265731.t001

Table 2. HF patient demographics and characteristics of procured human hearts (n = 18).

| ID # | Failing category | Sex | Age | Race | BMI  | HW (g) | Overall Dimensions (cm) | LV Wall (cm) | RV Wall (cm) | Septum (cm) |
|------|------------------|-----|-----|------|------|--------|-------------------------|-------------|-------------|-------------|
| FNH1 | ICM              | M   | 57  | C    | 30   | 619    | 10.5 11 10.5            | 1.2         | 0.9         | 1.1         |
| FNH2 | NICM             | F   | 32  | C    | 26   | 435    | 14.4 10.9 8            | 1.1         | 0.6         | 0.9         |
| FNH3 | NICM             | M   | 49  | C    | 31.3 | 1153   | 21 16 15               | 1.6         | 1           | 1.6         |
| FNH4 | NICM             | M   | 59  | C    | 27   | 972    | 14.5 16 14            | 1.5         | 0.5         | 1.7         |
| FNH5 | NICM             | M   | 56  | C    | 25.5 | 474    | 11 12.5 9.5           | 1.1         | 0.6         | 0.8         |
| FNH6 | NICM             | M   | 40  | C/AA | 25.6 | 747    | 12 15 11              | 1.4         | 0.9         | 1.3         |
| FNH7 | NICM             | F   | 39  | AA   | 33.9 | 365    | 10.7 13.5 10            | 1.3         | 0.8         | 1           |
| FNH8 | NICM             | F   | 51  | C    | 28.5 | 572    | - - -                | 2.5         | 1           | 2.4         |
| FNH9 | NICM             | M   | 64  | C    | 23.3 | 564    | 11 14 9.5              | 2.2         | 1.2         | 1.5         |

Failing human hearts with no hypothyroidism (FNH; n = 9)

| ID # | Failing category | Sex | Age | Race | BMI  | HW (g) | Overall Dimensions (cm) | LV Wall (cm) | RV Wall (cm) | Septum (cm) |
|------|------------------|-----|-----|------|------|--------|-------------------------|-------------|-------------|-------------|
| FH1  | ICM              | M   | 64  | C    | 27.4 | 27.4   | - - - - -                | -           | -           | -           |
| FH2  | ICM              | M   | 65  | C    | 24.5 | 621    | 12.5 11 8.5            | 1.9         | 0.9         | 0.8         |
| FH3  | ICM              | M   | 52  | C    | 23   | 498    | 14 12 11              | 1.5         | 0.7         | 1.3         |
| FH4  | ICM              | F   | 50  | C    | 33.5 | 486    | 14 13 11              | 1.2         | 0.6         | 1.8         |
| FH5  | ICM              | M   | 59  | C    | 32.5 | 530    | 10.5 10.5 11          | 1.5         | 0.8         | 1.1         |
| FH6  | NICM             | M   | 63  | C    | 23.5 | 329    | 14 10 10              | 1.5         | 1           | 1.1         |
| FH7  | NICM             | M   | 68  | C    | 25.6 | 768    | 16 15 14              | 1.4         | 0.8         | 1.2         |
| FH8  | NICM             | M   | 52  | C    | 28.3 | 390    | 10.5 10 8.5          | 1           | 0.7         | 1.3         |
| FH9  | NICM             | F   | 35  | C    | 28.7 | 262    | 7.5 9 7               | 1.2         | 0.7         | 0.8         |

Failing human hearts with hypothyroidism (FH; n = 9)

C/AA, Caucasian/African American; FH, failing with hypothyroidism; FNH, failing with no hypothyroidism; HF, heart failure; ICM, ischemic cardiomyopathy; NICM, non-ischemic cardiomyopathy; other abbreviations as in Table 1.

https://doi.org/10.1371/journal.pone.0265731.t002
roughly corresponds to sarcomere length of ~2.2 μm, which is near or at the in-vivo sarcomere length at end-diastole [31,32].

Baseline trabeculae function
Baseline contractile force and kinetics of contraction and relaxation were assessed at a frequency of 1 Hz once muscles had stabilized in the set-up. This frequency is close to the physiological normal resting in-vivo heart rate of ~60–70 bpm. The dimensions of muscles were measured under the stereo microscope (at 40x magnification, resolution of ~10 μm), and all recorded forces were normalized to the cross-sectional area of the trabecula. Average dimensions (width × thickness × length) of LV trabeculae from NF, FNH, and FH were (0.35 ± 0.03 × 0.23 ± 0.02 × 3.74 ± 0.42 mm), (0.53 ± 0.1 × 0.36 ± 0.06 × 2.74 ± 0.38 mm), and (0.46 ± 0.06 × 0.31 ± 0.04 × 2.9 ± 0.4 mm) respectively. There were no significant differences between the dimensions of the muscles of the three studied groups.

Assessment of contractile properties and kinetics of relaxation
The three main physiological modulators that regulate contractile strength: length-dependent activation, frequency-dependent activation, and β-adrenergic stimulation were assessed under near-physiological conditions. First, the effect of muscle length on developed force (F_{dev}) and kinetics was assessed at four different muscle lengths (set as a percentage of optimal length) and a constant frequency of 0.5 Hz. After force and kinetics were measured at L_{100}, the muscle length was reduced to 85% of L_{100} (L_{85%}), then 90% (L_{90%}), then 95% (L_{95%}), and then back again to L_{100}. Muscles were allowed to stabilize at each length before parameters were recorded. We assessed the effect of increasing stimulation frequencies (frequency-dependent activation) at L_{100} between 0.5 and 3 Hz, spanning the entire physiological range of a healthy adult human heart. Forces were allowed to reach a steady-state at each frequency (total of 6) before data were recorded (typically 2–3 minutes at each frequency). Lastly, the effects of β-adrenergic stimulation were assessed by a concentration-response curve with isoproterenol (1 nM– 1 μM) at a baseline stimulation frequency of 0.5 Hz and L_{100}.

Data analysis and statistics
A custom-made program in LabView (National Instruments) was used to analyze force and kinetic measurements. Muscle tensions were normalized to the cross-sectional area of the muscles and expressed as mN/mm². Statistical comparison of the mean values of contractile forces and kinetic parameters between NF, FNH, and FH groups was performed via one-way analysis of variance (ANOVA), or by two-way ANOVA for repeated measures. This comparison was then followed by Tukey’s post hoc multiple comparison test, comparing all pairs of columns. Unpaired two-tailed Student’s t-test was used to compare TSH levels between FNH and FH groups. Statistical significance was set at two-tailed P < 0.05. All data are presented as means ± standard error of the mean (SEM).

Results
Baseline contraction and relaxation kinetics
Active developed force (F_{dev}) of trabeculae isolated from FH hearts was the lowest among the groups and significantly different from NF trabeculae (9.2 ± 2.0 mN/mm² vs. 18.7 ± 3.0 mN/mm²; P = 0.03), while there was no significant difference in diastolic force (F_{dia}) between the three groups (Fig 1A). We analyzed the kinetic parameters of the same muscles, shown in Fig 1B, where we detected no significant difference in time from electrical stimulation to peak
tension (TTP) between NF, FNH, and FH trabeculae. Similarly, time from peak tension to 50% relaxation (RT50) and time from peak tension to 90% relaxation (RT90) were not significantly different between the three groups. Total twitch time, calculated as the time from stimulation to 90% relaxation time (note, 100% relaxation time cannot be accurately assessed as force asymptotically approaches resting tension), was also not significant. We found that trabeculae isolated from FNH hearts (90 ± 15 mN/mm²/s; \( P = 0.034 \)) and FH (76 ± 16 mN/mm²/s; \( P = 0.01 \)) had a significantly slower rate of tension rise (+dF/dt) compared to that of NF trabeculae (155 ± 20 mN/mm²/s). Rate of tension decline (-dF/dt) was significantly prolonged in FH hearts (42 ± 8 mN/mm²/s; \( P = 0.017 \)) compared to NF (-110 ± 24 mN/mm²/s), while there was no significant difference between the two failing groups (Fig 1C). However, the derivative of force (dF/dt) is highly dependent on the level of force. Both +dF/dt and -dF/dt were then normalized to the developed twitch tensions to obtain pure kinetic parameters [36]. The maximal kinetic rate of contraction (+dF/dt/F_{dev}) and the relaxation parameter (-dF/dt/F_{dev}) were not significantly different between groups (Fig 1D).

Fig 1. Contractile force and kinetics of NF trabeculae (n = 9) vs. failing trabeculae with no hypothyroidism (FNH; n = 9) and failing trabeculae with hypothyroidism (FH; n = 9) at baseline 1 Hz. (A) F_{dev} of NF trabeculae was significantly greater than that of FH trabeculae, while there was no significant difference in F_{dia} between the three groups. (B) TTP, RT50, RT90 and TT90 were not significantly different between groups. (C) +dF/dt was significantly prolonged in FNH and FH trabeculae compared to NF trabeculae, while -dF/dt was significantly slower in FH trabeculae compared to NF trabeculae. (D) +dF/dt/F_{dev} and -dF/dt/F_{dev} were not significantly different between all groups. Data are depicted as means ± SEM; One-way ANOVA followed by Tukey’s post-hoc test for multiple comparisons. +dF/dt, maximal rate of force development during contraction; -dF/dt, maximal rate of force decay during relaxation; +dF/dt/F_{dev}, maximal kinetic rate of contraction; -dF/dt/F_{dev}, maximal kinetic rate of relaxation; F_{dev}, active developed force; F_{dia}, diastolic force; FH, failing with hypothyroidism; FNH, failing with no hypothyroidism; NF, non-failing; RT50, time from peak tension to 50% relaxation; RT90, time from peak tension to 90% relaxation; TT90, time from stimulation to 90% relaxation time; TTP, time to peak tension.

https://doi.org/10.1371/journal.pone.0265731.g001
Impact of muscle length on contraction/relaxation and kinetics

In agreement with previous studies [37,38], increasing muscle length from L_{85} to L_{100} stepwise increased developed tensions in response to a change in muscle length in all groups to the same degree (at a constant frequency of 0.5 Hz) (Fig 2A). To investigate the true length-

![Fig 2](https://doi.org/10.1371/journal.pone.0265731.g002)

Fig 2. Length-dependent activation in NF trabeculae (n = 9) vs. failing trabeculae with no hypothyroidism (FNH; n = 9) and failing trabeculae with hypothyroidism (FH; n = 4). (A) Length dependent force development was virtually identical in all groups. (B) Same data as panel A, plotted to each muscle’s individual maximum to allow equal weight of each muscle in the statistical analysis. (C) F_{dia} increased by increasing the muscle length, and there was no difference in the degree of change in force between the three groups in response to length increase. (D) TTP in NF myocardium was markedly slowed down as muscle length increased rather than the two failing groups, while trabeculae isolated from FNH hearts showed a prolonged TTP overall different muscle lengths compared to both NF and FH hearts and became significantly different compared to NF at L_{85} (P = 0.013) and L_{90} (P = 0.032). (E) RT50 decreased as muscles were shortened from L_{100} to L_{85} and the degree of shortening was much obvious in NF group. (F) RT90 was not significantly different between the three groups at each respective muscle length and was faster as muscles were shortened. (G) +dF/dt and -dF/dt were prolonged in NF and failing groups as muscles were shortened and were not significantly different between groups. (H) +dF/dt/F_{dev} was sped up as muscles were shortened with no difference between groups. With the exception of trabeculae isolated from FNH hearts, -dF/dt/F_{dev} was also sped up in both NF and FH groups. Data are depicted as means ± SEM; A two-way repeated measures ANOVA followed by Tukey’s post hoc test for multiple comparisons; * indicates P < 0.05 significant difference between NF and FH groups; † indicates P < 0.05 significant difference between NF and FNH groups at corresponding muscle length. L_{100}, optimal muscle length; L_{85}, 85% of L_{100}; L_{90}, 90% of L_{100}; L_{95}, 95% of L_{100}; other abbreviations as in Fig 1.

https://doi.org/10.1371/journal.pone.0265731.g002
dependency, we plotted the data in Fig 2B, where developed forces were normalized to the maximal force of the muscle at L\(_{100}\). This normalization helps eliminate the effect of the absolute forces of the stronger muscles, which strongly control this presentation mode. Our results showed the linearity of this relationship with no difference between the three groups. Moreover, there was no difference in the degree of change in F\(_{dia}\) between groups in response to length increase (Fig 2C). Trabeculae from FNH hearts had a longer TTP overall different muscle lengths than those of NF and FH hearts, and this difference was statistically significant at L\(_{85}\) and L\(_{90}\) (204 ± 11 ms and 215 ± 12 ms, respectively) vs. NF trabeculae (157 ± 8 ms; \(P = 0.013\) and 173 ± 11 ms; \(P = 0.032\), respectively) (Fig 2D). RT50 and RT90 were not significantly different between groups at each respective muscle length (Fig 2E and 2F). Furthermore, +dF/dt and -dF/dt were faster as muscle length increased with no significant difference between NF and both failing groups at each respective muscle length (Fig 2G). In all groups, +dF/dt/F\(_{dev}\) was slowed down as muscle length increased. Similarly, -dF/dt/F\(_{dev}\) was slowed down except in FNH group where it sped up (Fig 2H).

**Impact of frequency on contraction/relaxation and kinetics**

Our data showed that NF myocardium typically displayed a positive force-frequency relationship (FFR) where F\(_{dev}\) increased between 0.5 and 2.5 Hz, while both FNH and FH myocardium had a flat or negative FFR between 0.5 and 2 Hz (Fig 3A). F\(_{dev}\) of both failing groups was significantly lower compared to NF group at frequencies ranging from 1.5–3 Hz. We normalized developed forces to 0.5 Hz to assess the changes in developed forces at higher frequencies and determine FFR (Fig 3B). This analysis also showed a positive FFR in NF myocardium and flat FFR between 0.5–2 Hz in both failing groups. The diastolic force was slightly decreased at 1 and 2 Hz in NF and failing groups, while it was much higher at 3 Hz than at 0.5 Hz (Fig 3C). No major alterations in most of the kinetic parameters were observed between groups. TTP shortened upon the increasing frequency of stimulation in all three groups. There were no differences between NF and the two failing groups at each respective frequency of stimulation (Fig 3D). In NF and failing groups, RT50 and RT90 shortened across the tested frequencies (Fig 3E and 3F). Both +dF/dt and -dF/dt of NF, as well as failing groups, sped up with frequency increase in all groups and were statistically significant between NF group and the two failing groups at 1.5–3 Hz (\(P < 0.05\)) (Fig 3G). Furthermore, both +dF/dt/F\(_{dev}\) and -dF/dt/F\(_{dev}\) were significantly faster in all groups upon increase the stimulation frequency (Fig 3H).

**Impact β-adrenergic stimulation on contraction/relaxation and kinetics**

NF myocardium exhibited significantly increased responses than both failing groups under full β-adrenergic stimulation (Fig 4A). Relative to baseline (no isoproterenol), isoproterenol-induced force development was similarly depressed in both failing groups, while statistical significance was reached at 30 nM, 0.1 µM, 0.3 µM, and 1 µM compared to NF myocardium (Fig 4B). Diastolic tension slightly decreased in the NF group and both failing groups over the concentration range, as shown in Fig 4C, without any significant difference between groups. Kinetics accelerated similarly in each group (curve shape is the same/highly similar), as illustrated for TTP (Fig 4D), RT50 (Fig 4E), and RT90 (Fig 4F) were shortened down almost similarly in all the three groups. In NF trabeculae, both +dF/dt and -dF/dt were sped up over the concentration range (Fig 4G). In failing groups, statistical significance compared to NF group was reached at 30 nM, 0.1 µM, 0.3 µM, and 1 µM. +dF/dt/F\(_{dev}\) was much faster throughout the concentration-response protocol in NF trabeculae compared to both failing groups and showed a significant difference compared to FNH at 0.3 µM and 1 µM. -dF/dt/F\(_{dev}\) was significantly faster in NF group vs. FNH group, mostly at higher concentrations (Fig 4H).
Clinical information was available for all HF patients with and without hypothyroidism in our study. The mean age was 56 years, with 22% female. In a recent study published by our

![Clinical information](https://doi.org/10.1371/journal.pone.0265731.g003)
laboratory, a total of 112 hearts [non-failing ($n = 58$) and failing ($n = 54$)] were used in an assessment of LV isolated muscle function. The results of unpaired two-tailed $t$-test (not reported) revealed that gender did not impact force within NF or even failing myocardium. Moreover, the interaction between the effects of gender and pathology was not significant on

Fig 4. β-adrenergic stimulation in NF trabeculae ($n = 9$) vs. failing trabeculae with no hypothyroidism (FNH; $n = 9$) and failing trabeculae with hypothyroidism (FH; $n = 4$). (A) $F_{dav}$ was increased in NF trabeculae upon addition of isoproterenol in a concentration dependent manner and was significantly greater than the increase in both failing groups. (B) Same data as panel A, plotted to each muscle’s force at baseline to allow equal weight of each muscle in the statistical analysis. (C) $F_{dav}$ slightly decreased in NF and both failing groups over the concentration range with no significant difference between the three groups. (D) TTP shortened almost similarly in all three groups upon increasing isoproterenol concentration. (E) RT50 slightly decreased as concentration increased from 1 nM to 1 μM in all three groups. (F) RT90 was not significantly different between the three groups over the concentration range. (G) $+dF/dt$ and $-dF/dt$ were sped up in NF and failing groups as isoproterenol concentration increased and were significantly faster in NF group compared to both failing groups at the concentration range of 30 nM—1 μM. (H) NF myocardium showed faster $+dF/dt/F_{dav}$ and $-dF/dt/F_{dav}$ throughout the concentration-response protocol compared to both failing groups with significantly faster $+dF/dt/F_{dav}$ at 0.3 μM and 1 μM and significantly faster $-dF/dt/F_{dav}$ at 30 nM, 0.1 μM and 1 μM vs. FNH myocardium. Data are depicted as means ± SEM; A two-way repeated measures ANOVA followed by Tukey’s post hoc test for multiple comparisons; * indicates $P < 0.05$ significant difference between NF and FH groups; † indicates $P < 0.05$ significant difference between NF and FNH groups at corresponding isoproterenol concentration. Abbreviations as in Fig 1.

https://doi.org/10.1371/journal.pone.0265731.g004
the Fdev parameter [33]. Accordingly, limited representation of female subjects in this cohort has no effect on the contractile force outcomes.

The New York Heart Association classification was predominantly class IV (88%) with a minority of class III (11%). All patients with hypothyroidism received levothyroxine treatment with a dose range of 25–200 μg/day. Likely due to this therapy, HF with hypothyroidism had TSH levels ranging from 0.05–8.19 mU/L, which were not significantly different from TSH levels of HF patients who had no thyroid dysfunction (4.28 ± 1.22 mU/L vs. 3.12 ± 0.49 mU/L; \( P = 0.41 \)). Information on whether patients started levothyroxine treatment before or after diagnosis with HF was not available.

**Discussion**

We reported here for the first time that hypothyroidism has no additional impact on the force of contraction and kinetics of contraction/relaxation of LV intact human myocardial muscle preparation isolated from end-stage failing heart different than the recognized alterations usually detected in such parameters in any end-stage failing heart without underlying thyroid dysfunction.

Our study was performed on end-stage HF, which is the most severe class of the four classes of HF as described in The New York Heart Association. Absence of any difference between failing hearts with or without hypothyroidism, may possibly be due to the profound effects of the advanced stage of HF that concealed any changes between the groups. Still, we cannot rule out the possibility of differences that may have been present at earlier stages of HF.

The relationship between hypothyroidism and heart diseases is not unidirectional. HF can lead to the down-regulation of the thyroid hormone signaling system in the heart [15]. In the failing heart, decreases of nuclear TR levels occur. In addition, HF may also alter the metabolism of thyroid hormones. Numerous reports from clinical and animal studies have documented altered thyroid hormone metabolism with low serum levels of T3 and T4 with HF in the context of the non-thyroidal illness syndrome. The hypoxia and the inflammatory response to HF are able to reduce the type 2 deiodinase (D2) activity in the cardiomyocytes, which results in a decrease of intracellular T3 bioavailability [39]. In a rodent model of cardiac disease, overexpression of D2 in the heart was able to enhance cardiac contractility while preventing cardiac functional deterioration and altered gene expression after pressure overload [40]. Hypoxia also can induce the expression of D3 deiodinase, which converts T4 to the deactivated rT3 metabolite in cardiomyocytes. In another study using rat model of right ventricular (RV) hypertrophy and failure, D3 activity increased in the chronically overloaded RV, whereas no changes were observed in the LV of the same heart [41]. The abnormalities in TRs and the decreased deiodinase activities could both lead to the development of important changes in cardiac gene expression, which are like those observed in hypothyroidism. Based on current findings, the American Heart Association in 2013 issued guidelines recommending that doctors test thyroid hormone levels in all patients with HF [42].

Clinical information for FH patients in our study revealed that they were all receiving THs replacement therapy, levothyroxine, but we have limited information about the circumstances of their diagnoses with HF and hypothyroidism as well as when they started receiving levothyroxine treatment. Our statistical analysis did not show significant differences in FH patients’ TSH levels compared to the FNH patients, which possibly reflects the efficiency and accuracy of the thyroid hormone doses used in treating these patients. Previous studies have reported that TH replacement therapy in patients with hypothyroidism generally may lower peripheral vascular resistance, reverse atherosclerosis, and improve myocardial perfusion [43]. Treatment of overt hypothyroidism and subclinical hypothyroidism using levothyroxine has proven its
ability to prevent progressive LV dysfunction by improving systolic and diastolic dysfunctions, systemic vascular resistance, and endothelial function, which can improve cardiac output (CO) thereby increasing CO and stroke volume [44,45]. Moreover, levothyroxine in replacement doses is recommended by international guidelines and expert opinions in patients with serum TSH above 10 mU/L [46]. Since patients in our study underwent screening for their heart conditions, they were all receiving treatment for their thyroid problems. It was unfeasible to find samples from HF patients who got diagnosed with hypothyroidism and didn’t receive any treatment for that problem. Lacking such data, didn’t allow us to confirm the possible role of levothyroxine in controlling the anticipated hypothyroidism myocardial alterations in FH group. Indeed, more studies are still needed to investigate the effects of THs supplementation such as levothyroxine on contractile force and kinetic parameters of failing human myocardium and explore its full potential in improving cardiovascular performance and cardiovascular outcomes of HF associated with hypothyroidism.

Our results showed that the active developed force of contraction at resting heart rate (1 Hz and L100) was significantly lower in FH compared to NF group at resting. The level of developed force in failing preparations compared to non-failing can be decreased as shown in a previous study performed on muscle strip and myocytes [47], increased as in isolated myocytes preparation [48] or reported no significant difference as we shown before in trabeculae [49]. Changes in myofilament calcium sensitivity are suggested to be one of the reasons behind altered force development capability. Since we did not measure this parameter, we cannot assume that the difference found in our study directly relates to hypothyroidism. Our present data also showed that there were no differences in the pure kinetic parameters (+dF/dt/Fdev and -dF/dt/Fdev) between the NF and both failing groups when measured at 1 Hz and L100. Previous studies on LV muscles of failing human myocardium confirm these findings [50,51]. Recent studies from our laboratory showed that when assessed in high numbers, the statistical power may be sufficient to detect small differences in contractile kinetics [32,49], but given the low numbers of hypothyroid hearts available, it was not feasible to obtain larger number of hearts where subtle differences may become statistically significant.

Length-dependent regulation is one of the main regulatory pathways that impacts cardiac force. In our study, the length-dependent activation mechanism in both failing groups was completely preserved, both in the regulation of active force development and in the regulation of kinetics. With an increase in muscle length, all three groups responded to a similar quantitative and qualitative increase in force and slowing of kinetics similar to what had been reported before in different studies [32,52].

The LV myocardium of failing hearts (with or without thyroid dysfunction) in the present study had the expected blunt FFR, a classical hallmark that has been extensively observed in failing human myocardium [32,48,49]. Alterations in calcium handling mechanisms are mainly responsible for such abnormal FFR [53]. Rates of contraction and relaxation were significantly slower in failing myocardium over the entire range of stimulating frequencies. Defective calcium homeostasis in failing myocardium is partially responsible for slow relaxation and poor contractile response to increasing stimulation frequency.

Finally, in close agreement with previous studies [32,49], the β-adrenergic response was also blunted in both failing groups. The mechanisms responsible for β-adrenergic desensitization have been attributed to receptor desensitization and/or downregulation following prolonged exposure to catecholamines [54]. A significant slow-down of contraction and relaxation rates was observed upon stimulation, similar to our results in frequency-dependent activation as previously reported [32].
Limitations of the study
In order to detect small differences in contractile responses or changes in kinetics, in combination with the large variability (mostly due to genetic variety) in patient samples, much larger \( n \)-numbers of samples would be needed. However, given the fact that this study took over 8 years to complete, a study with the same statistical power that we completed in a decade-long study recently reported [32], it would take several decades to complete. Hence, we cannot exclude subtle differences in force or kinetics at the end-stage of HF between patients with hypothyroidism, and those without.

It was unfeasible to find samples from HF patients who got diagnosed with hypothyroidism and didn’t receive any treatment to compare against and confirm if levothyroxine played a role in controlling the anticipated hypothyroidism myocardial alterations in FH group in our study.

We did not assess protein levels and phosphorylation levels in this study. The phosphorylation status of several contractile proteins has been shown previously to be impacted by both pre-load [55], and by frequency [56] and this phosphorylation profile is impacted in disease [57]. Per se, a correlative study on the impact of phosphorylation on force development and regulation needs samples at different contractile states (different lengths, frequencies, and beta-stimulation), which was not possible in our studies. In addition, the phosphorylation status of procured quiescent tissue, under unloaded conditions, may thus provide, at best, a weak substitute for actual experiments on tissue in contractile homeostasis. Although we have collected several muscles at homeostasis, we can unfortunately only freeze each muscle in this study under 1 condition at the very end of the study (typically in presence of maximal \( \beta \)-adrenergic stimulation). Studies with human tissue frozen at different homeostasis (i.e., at different pre-load, and at different frequencies), are needed in the future to shed more light on the underlying mechanisms”.

Conclusions
Hypothyroidism didn’t show any additional impact on the force of contraction and kinetics of contraction/relaxation in end-stage failing hearts. Absence of any difference may possibly be due to the profound effects of the advanced stage of HF that concealed any changes between the two groups. Still, we cannot exclude the possibility of differences that may have been present at earlier stages of HF. Therefore, future studies are critically needed to investigate the impact of hypothyroidism on the earlier stages. Since it was unfeasible to find samples from HF patients who got diagnosed with hypothyroidism and not receiving treatment to compare against, we couldn’t confirm the possible role of levothyroxine in controlling the anticipated hypothyroidism myocardial alterations in the FH group in our study. The effects of THs supplementation such as levothyroxine on contractile force and kinetic parameters of such failing myocardium, still needs further exploration.

Supporting information
S1 Table. TSH level of heart failure patients with no thyroid dysfunction/with hypothyroidism and their Levothyroxine treatment doses.
(DOCX)

S1 Dataset.
(XLSX)

S2 Dataset.
(XLSX)
Acknowledgments
The authors would like to thank OSU Division of Cardiac Surgery transplant coordinators and surgeons for their help in logistics and consenting patients. The authors would like to thank the surgeons and coordinators of the Lifeline of Ohio for help with obtaining the donor hearts and related clinical information.

Author Contributions
Conceptualization: Mohammad T. Elnakish, Paul M. L. Janssen.
Data curation: Nancy S. Saad, Mohammed A. Mashali, Mohammad T. Elnakish, Austin Hare, Courtney M. Campbell, Salome A. Kiduko, Kyra K. Peczkowski, Amanda W. Huang, Farbod Fazlollahi, Gina S. Torres Matias.
Formal analysis: Nancy S. Saad.
Funding acquisition: Paul M. L. Janssen.
Investigation: Nancy S. Saad, Mohammed A. Mashali, Mohammad T. Elnakish, Austin Hare, Courtney M. Campbell, Salome A. Kiduko, Kyra K. Peczkowski, Amanda W. Huang, Farbod Fazlollahi, Gina S. Torres Matias, Bryan A. Whitson, Nahush A. Mokadam.
Methodology: Paul M. L. Janssen.
Project administration: Paul M. L. Janssen.
Resources: Amany A. E. Ahmed, Bryan A. Whitson, Nahush A. Mokadam, Paul M. L. Janssen.
Software: Paul M. L. Janssen.
Supervision: Amany A. E. Ahmed, Bryan A. Whitson, Nahush A. Mokadam.
Writing – original draft: Nancy S. Saad, Mohammed A. Mashali.
Writing – review & editing: Mohammed A. Mashali, Austin Hare, Courtney M. Campbell, Salome A. Kiduko, Kyra K. Peczkowski, Amanda W. Huang, Farbod Fazlollahi, Gina S. Torres Matias, Amany A. E. Ahmed, Bryan A. Whitson, Nahush A. Mokadam, Paul M. L. Janssen.

References
1. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009; 53(15):1343–82.
2. Braunwald E. Heart Failure. JACC: Heart Failure. 2013; 1(1):1–20. https://doi.org/10.1016/j.jchf.2012.10.002 PMID: 24621794
3. Benjamin EJ, Muntner P, Bittencourt MS. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation. 2019; 139(10):e56–e528. https://doi.org/10.1161/CIR.0000000000006699 PMID: 30700139
4. Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, et al. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004; 292(3):344–50. https://doi.org/10.1001/jama.292.3.344 PMID: 15265849
5. Pantos CI, Malliopoulos VA, Karamanoli EP, Paizis IA, Steinberg N, et al. Long-term thyroxine administration protects the heart in a pattern similar to ischemic preconditioning. Thyroid. 2002; 12(4):325–9. https://doi.org/10.1089/10507250252949469 PMID: 12034058

6. Maia AL, Kim BW, Huang SA, Harney JW, Larsen PR. Type 2 iodothyronine deiodinase is the major source of plasma T3 in euthyroid humans. J Clin Invest. 2005; 115(9):2524–33. https://doi.org/10.1172/JCI25083 PMID: 16127464

7. Klein I, Danzi S. Thyroid disease and the heart. Circulation. 2007; 116(15):1725–35. https://doi.org/10.1161/CIRCULATIONAHA.106.678326 PMID: 17923583

8. Fazio S, Palmieri EA, Lombardi G, Biondi B. Effects of thyroid hormone on the cardiovascular system. Recent Prog Horm Res. 2004; 59(1):31–50. https://doi.org/10.1210/rp.59.1.31 PMID: 14749496

9. Biondi B, Palmieri EA, Lombardi G, Fazio S. Subclinical hypothyroidism and cardiac function. Thyroid. 2002; 12(6):505–10. https://doi.org/10.1089/105072502760143890 PMID: 12165114

10. Liu Y, Redetzke RA, Said S, Pottala JV, de Escobar GM, Gerdes AM. Serum thyroid hormone levels may not accurately reflect thyroid tissue levels and cardiac function in mild hypothyroidism. American Journal of Physiology-Heart and Circulatory Physiology. 2008; 294(5):H2137–H43. https://doi.org/10.1152/ajpheart.01379.2007 PMID: 18310509

11. Liu Z, Gerdes AM. Influence of hypothyroidism and the reversal of hypothyroidism on hemodynamics and cell size in the adult rat heart. J Mol Cell Cardiol. 2004; 36(10):1501–10. https://doi.org/10.1016/j.yjmcc.2004.07.034 PMID: 15328997

12. Angus C, Kuzman JA, Said S, Anderson BE, Wang X, Gerdes AM. Low thyroid function leads to cardiac atrophy with chamber dilatation, impaired myocardial blood flow, loss of arterioles, and severe systolic dysfunction. Circulation. 2005; 112(20):3122–30. https://doi.org/10.1161/CIRCULATIONAHA.105.572883 PMID: 16275864

13. Wu Y, Koenig RJ. Gene regulation by thyroid hormone. Trends Endocrinol Metab. 2000; 11(6):207–11. https://doi.org/10.1016/s1043-2760(00)00263-0 PMID: 10878749

14. Vargas-Uricoechea H, Sierra-Torres CH. Thyroid hormones and the heart. Horm Mol Biol Clin Invest. 2014; 18(1):15–26. https://doi.org/10.1515/hmbci-2013-0059 PMID: 14749496

15. Biondi B, Klein I. Hypothyroidism as a risk factor for cardiovascular disease. Endocrine. 2004; 24(1):1–13. https://doi.org/10.1080/ENDO-24:1.001 PMID: 15249698

16. Jabbar A, Pingitore A, Pearce SH, Zaman A, Iervasi G, Razvi S. Thyroid hormones and cardiovascular disease. Nature Reviews Cardiology. 2017; 14(1):39–55. https://doi.org/10.1038/nrcardio.2016.174 PMID: 27811932
27. Biondi B, Palmieri EA, Lombardi G, Fazio S. Subclinical thyroid dysfunction and the heart. Ann Intern Med. 2003; 139(10):866–7. https://doi.org/10.7326/0003-4819-139-10-200311180-00022 PMID: 14623630

28. Gencer B, Collet T-H, Virgini V, Bauer DC, Gussekloo J, Cappola AR, et al. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. Circulation. 2012; 126(9):1040–9. https://doi.org/10.1161/CIRCULATIONAHA.112.096024 PMID: 22621943

29. Kinugawa K, Minobe WA, Wood WM, Ridgway EC, Baxter JD, Ribeiro RC, et al. Signaling pathways responsible for fetal gene induction in the failing human heart: evidence for altered thyroid hormone receptor gene expression. Circulation. 2001; 103(8):1089–94. https://doi.org/10.1161/01.cir.103.8.1089 PMID: 11224711

30. Kannan L, Shaw PA, Morley MP, Brandimarto J, Fang JC, Sweltzer NK, et al. Thyroid dysfunction in heart failure and cardiovascular outcomes. Circ Heart Fail. 2018; 11(12):e005266. https://doi.org/10.1161/CIRCHEARTFAILURE.118.005266 PMID: 30562095

31. Saad NS, Elnakhish MT, Brundage EA, Blesiadecki BJ, Kilic A, Ahmed AA, et al. Assessment of PKA and PKC inhibitors on force and kinetics of non-failing and failing human myocardium. Life Sci. 2018; 215:119–27. https://doi.org/10.1016/j.lfs.2018.10.065 PMID: 30399377

32. Mashali MA, Saad NS, Canan BD, Elnakhish MT, Milani-Nejad N, Chung J-H, et al. Impact of etiology on force and kinetics of left ventricular end-stage failing human myocardium. J Mol Cell Cardiol. 2021.

33. Mashali MA, Saad NS, Canan BD, Elnakhish MT, Milani-Nejad N, Chung J-H, et al. Impact of etiology on force and kinetics of left ventricular end-stage failing human myocardium. J Mol Cell Cardiol. 2021; 156:7–19. https://doi.org/10.1016/j.yjmcc.2021.03.007 PMID: 33766524

34. Repas SJ, Saad NS, Janssen PM, Elnakhish MT. Memantine, an NMDA receptor antagonist, prevents thyroid-induced hypertension, but not cardiac remodeling. J Cardiovasc Pharmacol. 2017; 70(5):305–13. https://doi.org/10.1097/FJC.0000000000000521 PMID: 29112047

35. Saad NS, Floyd K, Ahmed AA, Mohler PJ, Janssen PM, Elnakish MT, et al. Impact of etiology on systolic and diastolic cardiac function in patients with subclinical hypothyroidism. J Clin Endocrinol Metab. 1999; 84(6):2064–7. https://doi.org/10.1210/jcem.84.6.8985 PMID: 10601072103 PMID: 16595628

36. Janssen PM. Myocardial contraction-relaxation coupling. Am J Physiol Heart Circ Physiol. 2010; 299(6):H1741–H9. https://doi.org/10.1152/ajpheart.2009.085529 PMID: 20852049

37. Holubarsch C, Ruf T, Goldstein DJ, Ashton RC, Nickl W, Pieske B, et al. Existence of the Frank-Starling mechanism in the failing human heart: investigations on the organ, tissue, and sarcomere levels. Circulation. 1996; 94(4):683–9. https://doi.org/10.1161/01.cir.94.4.683 PMID: 8772688

38. Wei J, Eschenhagen T, Hirt S, Magnussen O, Mittmann C, Remmers U, et al. Preserved Frank-Starling mechanism in human end stage heart failure. Cardiovasc Res. 1998; 37(2):541–8. https://doi.org/10.1016/s0008-6363(97)00227-7 PMID: 9614508

39. Mario S, Horvath TL. Type 3 deiodinase in hypoxia: to cool or to kill? Cell Metab. 2008; 7(5):363–4. https://doi.org/10.1016/j.cmet.2008.04.008 PMID: 18460327

40. Trivieri MG, Oudit GY, Sah R, Kerfant B-G, Sun H, Gramolini AO, et al. Cardiac-specific elevations in thyroid hormone enhance contractility and prevent pressure overload-induced cardiac dysfunction. Proceedings of the National Academy of Sciences. 2006; 103(15):6043–8. https://doi.org/10.1073/pnas.0601072103 PMID: 16595628

41. Wassen F, Schiel AE, Kuiper G, Kaptein E, Bakker O, Visser TJ, et al. Induction of thyroid hormone-degrading deiodinase in cardiac hypertrophy and failure. Endocrinology. 2002; 143(7):2812–5. https://doi.org/10.1210/endo.143.7.8985 PMID: 12072417

42. Yancy C, Jessup M, Bozkurt B, Butler J, Casey D Jr, Colvin M, et al. ACC/AHA/HFSA focused update of the 2013 ACCF/AHA Guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017; 136: e137–e161. Blood pressure and heart failure. 2017. https://doi.org/10.1161/CIRCHEARTFAILURE.118.005266 PMID: 28455343

43. Grais IM, Sowers JR. Thyroid and the heart. Am J Med. 2014; 127(8):691–8. https://doi.org/10.1016/j.amjmed.2014.03.009 PMID: 24662620

44. Biondi B, Fazio S, Palmieri EA, Carella C, Panza N, Cittadini A, et al. Left ventricular diastolic dysfunction in patients with subclinical hypothyroidism. J Clin Endocrinol Metab. 1999; 84(6):2064–7. https://doi.org/10.1210/jcem.84.6.5733 PMID: 10372711

45. Ripoli A, Pingitore A, Favilli B, Bottone A, Turchi S, Osman NF, et al. Does subclinical hypothyroidism affect cardiac pump performance?: Evidence from a magnetic resonance imaging study. J Am Coll Cardiol. 2005; 45(3):439–45. https://doi.org/10.1016/j.jacc.2004.10.044 PMID: 15680725
46. Biondi B, Wartofsky L. Treatment with thyroid hormone. Endocr Rev. 2014; 35(3):433–512. https://doi.org/10.1210/er.2013-1083 PMID: 24433025

47. Pieske B, Maier LS, Piacentino V III, Weisser J, Hasenfuss G, Houser S. Rate dependence of [Na+]i and contractility in nonfailing and failing human myocardium. Circulation. 2002; 106(4):447–53. https://doi.org/10.1161/01.cir.0000023042.50192.f4 PMID: 12135944

48. Chaudhary KW, Rossman EI, Piacentino V, Kenessey A, Weber C, Gaughan JP, et al. Altered myocardial Ca2+ cycling after left ventricular assist device support in the failing human heart. J Am Coll Cardiol. 2004; 44(4):837–45. https://doi.org/10.1016/j.jacc.2004.05.049 PMID: 15312868

49. Chung J-H, Martin BL, Canan BD, Elnakish MT, Milani-Nejad N, Saad NS, et al. Etiology-dependent impairment of relaxation kinetics in right ventricular end-stage failing human myocardium. J Mol Cell Cardiol. 2018; 121:81–93. https://doi.org/10.1016/j.yjcc.2018.07.005 PMID: 29981798

50. Pieske B, Sütterlin M, Schmidt-Schweda S, Minami K, Meyer M, Olschewski M, et al. Diminished post-rest potentiation of contractile force in human dilated cardiomyopathy. Functional evidence for alterations in intracellular Ca2+ handling. J Clin Invest. 1996; 98(3):764–76. https://doi.org/10.1172/JCI118849 PMID: 8698869

51. Hasenfuss G, Mulieri L, Leavitt B, Allen P, Haeberle J, Alpert N. Alteration of contractile function and excitation-contraction coupling in dilated cardiomyopathy. Circ Res. 1992; 70(6):1225–32. https://doi.org/10.1161/01.res.70.6.1225 PMID: 1576741

52. Milani-Nejad N, Chung J-H, Canan BD, Davis JP, Fedorov VV, Higgins RS, et al. Insights into length-dependent regulation of cardiac cross-bridge cycling kinetics in human myocardium. Arch Biochem Biophys. 2016; 601:48–55. https://doi.org/10.1016/j.abb.2016.02.005 PMID: 26854725

53. Endoh M. Force–frequency relationship in intact mammalian ventricular myocardium: physiological and pathophysiological relevance. Eur J Pharmacol. 2004; 500(1–3):73–86. https://doi.org/10.1016/j.ejphar.2004.07.013 PMID: 15464022

54. Bristow MR, Ginsburg R, Minobe W, Cubiciotti RS, Sageman WS, Lurie K, et al. Decreased catecholamine sensitivity and β-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982; 307(4);205–11. https://doi.org/10.1056/NEJM1982072223070401 PMID: 6283349

55. Monasky MM, Taglieri DM, Jacobson AK, Haizlip KM, Solaro RJ, Janssen PM. Post-translational modifications of myofilament proteins involved in length-dependent prolongation of relaxation in rabbit right ventricular myocardium. Archives of biochemistry and biophysics. 2013; 535(1):22–9. Epub 2012/10/23. https://doi.org/10.1016/j.abb.2012.10.005 PMID: 23085150; PubMed Central PMCID: PMC3640662.

56. Varian KD, Janssen PM. Frequency dependent acceleration of relaxation involves decreased myofilament calcium sensitivity. American Journal of Physiology-Heart and Circulatory Physiology. 2007; 292(5):H2212–H9. Epub 2007/01/09. https://doi.org/10.1152/ajpheart.00778.2006 PMID: 17209002.

57. Varian KD, Kitjawornrat A, Gupta SC, Torres CA, Monasky MM, Hiranandani N, et al. Impairment of Diastolic Function by Lack of Frequency-Dependent Myofilament Desensitization in Rabbit Right Ventricular Hypertrophy. Circulation: Heart Failure. 2009; 2(9):472–81. https://doi.org/10.1161/CIRCHEARTFAILURE.109.853200 PMID: 19809378